Table 5.
Univariate and multivariate Cox analysis of OS for patients treated with CapTem regimen from baseline (since CapTem initiation).
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Gender | 0.396 | |||
| Female | 1 | |||
| Male | 31.571 (0.011–91454.19) | |||
| Age | 0.013* | 0.035* | ||
| <50 | 1 | 1 | ||
| ⩾50 | 15.142 (1.779–128.878) | 11.214 (1.189–105.796) | ||
| Inheritance | 0.308 | |||
| Sporadic | 1 | |||
| Familial (MEN1) | 3.062 (0.356–26.371) | |||
| Functional status | 0.161 | |||
| Nonfunctioning | 1 | |||
| Functioning | 3.262 (0.625–17.034) | |||
| TNM | 0.855 | |||
| III | 1 | |||
| IV | 0.820 (0.098–6.885) | |||
| Ki67 index | 0.077 | |||
| ⩽10% | 1 | |||
| >10% | 0.144 (0.017–1.229) | |||
| Mitosis | 0.661 | |||
| ⩽10 | 1 | |||
| >10 | 1.620 (0.188–13.956) | |||
| MGMT expression | 0.314 | |||
| Negative to moderate | 1 | |||
| High | 3.216 (0.331–31.233) | |||
| FDG-SUVmax (tumor/liver) | 0.332 | |||
| ⩽2 | 1 | |||
| >2 | 33.178 (0.028–39022.579) | |||
| SSA-SUVmax (tumor/liver) | 0.340 | |||
| ⩽1 | 1 | |||
| >1 | 2.080 (0.463–9.354) | |||
| Prior surgery | 0.380 | |||
| No | 1 | |||
| Yes | 0.479 (0.093–2.475) | |||
| CapTem line of treatment | 0.897 | |||
| First line (naïve) | 1 | |||
| ⩾Second line (pretreated) | 0.905 (0.200–4.101) | |||
| Lymph node metastasis | 0.611 | |||
| No | 1 | |||
| Yes | 1.733 (0.208–14.416) | |||
| Pleura metastasis | 0.212 | |||
| No | 1 | |||
| Yes | 0.260 (0.031–2.161) | |||
| Pericardium metastasis | 0.784 | |||
| No | 1 | |||
| Yes | 0.743 (0.089–6.191) | |||
| Lung metastasis | 0.859 | |||
| No | 1 | |||
| Yes | 0.825 (0.098–6.940) | |||
| Pancreas metastasis | 0.679 | |||
| No | 1 | |||
| Yes | 1.616 (0.166–15.681) | |||
| Liver metastasis | 0.097 | |||
| No | 1 | |||
| Yes | 6.840 (0.704–66.471) | |||
| Bone metastasis | 0.412 | |||
| No | 1 | |||
| Yes | 0.527 (0.114–2.436) | |||
| Blood parameters | ||||
| NLR | 0.991 (0.819–1.200) | 0.927 | ||
| LMR | 1.051 (0.646–1.712) | 0.840 | ||
| PLR | 0.393 (0.089–1.730) | 0.217 | ||
| AFP | 57664.187 (0.041–8094E+10) | 0.129 | ||
| CEA | 3.105 (0.556–17.345) | 0.197 | ||
| CA125 | 1.027 (1.005–1.049) | 0.015* | 1.059 (0.746–1.505) | 0.748 |
| SCC | 0.627 (0.005–73.402) | 0.848 | ||
| CA199 | 1.112 (1.108–1.215) | 0.018* | 0.857 (0.205–3.588) | 0.833 |
| PIVKA-II | 1.840 (0.007–513.518) | 0.832 | ||
| NSE | 1.382 (0.984–1.943) | 0.062 | ||
| CFRA21-1 | 1.384 (0.584–3.279) | 0.460 | ||
| ProGRP | 1.012 (0.966–1.059) | 0.620 | ||
| LDH | 0.424 (0.033–5.397) | 0.508 | ||
AFP, alpha-fetoprotein; CA125, carbohydrate antigen 125; CA199, carbohydrate antigen 199; CapTem, capecitabine and temozolomide; CEA, carcinoembryonic antigen; CFRA21-1, cytokeratin 19 fragment; FDG-SUVmax, fluorodeoxyglucose standardized uptake value maximum; LDH, lactate dehydrogenase; LMR, lymphocyte-to-monocyte ratio; MGMT, O6-methylguanine DNA methyltransferase; NLR, neutrophil-to-lymphocyte ratio; NSE, protein induced by vitamin K absence or antagonist II; OS, overall survival; PIVKA-II, protein induced by vitamin K absence or antagonist II; PLR, platelet-to-lymphocyte ratio; ProGRP, pro-gastrin-releasing peptide; SCC, squamous cell carcinoma antigen; SSA-SUVmax, somatostatin analogues standardized uptake value maximum; TNM, tumor-node-metastasis.
The bold values indicate significant values.